<?xml version="1.0" encoding="UTF-8"?>

<rootTag>
  <Award>
    <AwardTitle>SBIR Phase I: New Electrogenerated Chemoluminescence (ECL) Approach for High-Sensitivity, Hand-Held DNA Assay System for Security and Healthcare Applications</AwardTitle>
    <AwardEffectiveDate>07/01/2004</AwardEffectiveDate>
    <AwardExpirationDate>03/31/2005</AwardExpirationDate>
    <AwardAmount>99998</AwardAmount>
    <AwardInstrument>
      <Value>Standard Grant</Value>
    </AwardInstrument>
    <Organization>
      <Code>07070000</Code>
      <Directorate>
        <LongName>Directorate For Engineering</LongName>
      </Directorate>
      <Division>
        <LongName>Div Of Industrial Innovation &amp; Partnersh</LongName>
      </Division>
    </Organization>
    <ProgramOfficer>
      <SignBlockName>George B. Vermont</SignBlockName>
    </ProgramOfficer>
    <AbstractNarration>This Small Business Innovation Research (SBIR) Phase I research project is to develop and integrate a novel electrogenerated chemoluminescence (ECL)-based detection method into a handheld microfluidic bioanalyzer targeted ultimately at point-of-care and point-of-need in-vitro diagnostics for health care and safety/security applications. The detection method, which converts molecular redox events into optical signals, has low power requirements and needs no ancillary components such as an excitation laser or a potentiostat. Relative to existing ECL assays, the key innovation in this project is that the analyte-specific label and signal-generating reporter are two separate molecules in different spatial locations. The signal is generated by electronically coupling these two molecules using microfluidic and electronic circuitry integrated within a consumable fluidic cartridge, which also accepts the sample and admixes the assay reagents. &lt;br/&gt;&lt;br/&gt;The commercial application of this project will be to make available a low-power, lightweight, high-sensitivity handheld bioanalyzer. This bioanalyzer will enable multiplexed nucleic acid assays, addressing needs of the healthcare industry, and defense and security agencies.</AbstractNarration>
    <MinAmdLetterDate>05/26/2004</MinAmdLetterDate>
    <MaxAmdLetterDate>11/08/2004</MaxAmdLetterDate>
    <ARRAAmount/>
    <AwardID>0420192</AwardID>
    <Investigator>
      <FirstName>David</FirstName>
      <LastName>Albagli</LastName>
      <EmailAddress>dalbagli@eclipsesciences.com</EmailAddress>
      <StartDate>05/26/2004</StartDate>
      <EndDate>08/02/2004</EndDate>
      <RoleCode>Former Principal Investigator</RoleCode>
    </Investigator>
    <Investigator>
      <FirstName>Ming</FirstName>
      <LastName>Tan</LastName>
      <EmailAddress>mtan@eclipsesciences.com</EmailAddress>
      <StartDate>08/02/2004</StartDate>
      <EndDate/>
      <RoleCode>Principal Investigator</RoleCode>
    </Investigator>
    <Institution>
      <Name>Eclipse Sciences, Inc.</Name>
      <CityName>Los Gatos</CityName>
      <ZipCode>950325102</ZipCode>
      <PhoneNumber>6504900788</PhoneNumber>
      <StreetAddress>101 Bacigalupi Drive</StreetAddress>
      <CountryName>United States</CountryName>
      <StateName>California</StateName>
      <StateCode>CA</StateCode>
    </Institution>
    <FoaInformation>
      <Code>0308000</Code>
      <Name>Industrial Technology</Name>
    </FoaInformation>
  </Award>
</rootTag>
